Evolutionary Genomics, Inc. (FNAM) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerEvolutionary Genomics, Inc. (FNAM) trades at $0.0002. Evolutionary Genomics, Inc. is a biotechnology company focused on identifying beneficial genes in humans, animals, and crops. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for FNAM: FNAM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates FNAM against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
FNAM: the 2 scored disciplines are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Evolutionary Genomics, Inc. (FNAM) Healthcare & Pipeline Overview
Evolutionary Genomics, Inc. specializes in genomic research to enhance agricultural traits through its proprietary Adapted Traits Platform, catering to a diverse clientele that includes governmental and commercial entities.
What Is the Investment Thesis for FNAM?
Evolutionary Genomics, Inc. presents a unique value proposition through its Adapted Traits Platform, which addresses critical agricultural challenges such as food security and climate resilience. The global agricultural biotechnology market is projected to reach $50 billion by 2027, driven by increasing demand for genetically enhanced crops. Evolutionary Genomics’ focus on enhancing traits like drought tolerance and pest resistance positions it strategically within this growing market. The company's partnerships with governmental and non-profit organizations provide a stable revenue stream and enhance its credibility in the industry. However, the company faces risks associated with regulatory approvals and competition from larger biotechnology firms, which could impact its growth trajectory. Investors may want to evaluate these factors as they assess the company's potential for long-term success.
Based on FMP financials and quantitative analysis
FNAM Key Highlights
Market Cap: $0.00B, indicating a nascent stage with potential for growth as the biotechnology sector expands.
- Beta: -0.13, suggesting low volatility compared to the broader market.
- No dividend yield, reflecting a focus on reinvestment for growth.
- Small team of 2 employees, enabling agile decision-making and innovation.
- Established in 1990, showcasing over three decades of expertise in the biotechnology field.
Who Are FNAM's Competitors?
FNAM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MON Monument Circle Acquisition Corp. | $10.07 | +0.20% | — | |
| SYT SYLA Technologies Co., Ltd. American Depositary Shares | $2.26 | 0.00% | — | |
| RLYB Rallybio Corporation | $16.75 | -1.30% | $88.9M | 825-pillar |
| ICCC ImmuCell Corporation | $9.91 | +0.05% | $89.7M | 775-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.74 | -0.38% | $194M | 785-pillar |
| NAGE Niagen Bioscience Inc | $3.04 | -0.49% | $242M | 665-pillar |
| QTTB Q32 Bio Inc. | $10.93 | +1.96% | $325M | 685-pillar |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | 0.00% | $416M | 689-signal |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are FNAM's Key Strengths?
Proprietary Adapted Traits Platform for identifying beneficial genes.
- Established presence in the biotechnology sector since 1990.
- Diverse clientele including government and commercial entities.
What Are FNAM's Weaknesses?
Limited workforce of only 2 employees, which may restrict operational capacity.
- No current revenue generation reported, indicating early-stage development.
- Dependence on external partnerships for funding and growth.
What Could Drive FNAM Stock Higher?
Expansion of the Adapted Traits Platform to include new genetic markers.
- Research partnerships with governmental organizations to enhance agricultural productivity.
- Development of new applications for the Adapted Traits Platform in various crop types.
What Are the Key Risks for FNAM?
Financial-distress signal — its Altman Z-Score of -14.34 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles that could delay product development and market entry.
- Competition from larger biotechnology firms with more resources.
- Market volatility affecting funding and investment in agricultural biotechnology.
What Are the Growth Opportunities for FNAM?
- Growth opportunity 1: The global agricultural biotechnology market is projected to reach $50 billion by 2027, driven by the need for sustainable agricultural practices. Evolutionary Genomics, Inc.'s Adapted Traits Platform can capitalize on this trend by providing innovative solutions for crop enhancement, positioning the company to capture market share as demand for genetically improved crops increases.
- Growth opportunity 2: As climate change impacts agriculture, the need for drought-resistant crops is becoming increasingly urgent. Evolutionary Genomics' focus on enhancing drought tolerance through its proprietary technology aligns with this market need, potentially opening new revenue streams through partnerships with agricultural firms seeking to improve crop resilience.
- Growth opportunity 3: The rise of precision agriculture technologies presents an opportunity for Evolutionary Genomics to integrate its genetic insights with data-driven farming practices. By collaborating with technology firms in this space, the company can enhance its offerings and tap into a growing market segment that values data-backed agricultural solutions.
- Growth opportunity 4: The increasing emphasis on food security globally is driving investments in agricultural research and development. Evolutionary Genomics can leverage its expertise to secure funding from governmental and non-profit organizations focused on enhancing food production, thereby expanding its operational capacity and market reach.
- Growth opportunity 5: The trend towards organic and non-GMO crops is gaining momentum, with consumers increasingly prioritizing sustainably sourced food. Evolutionary Genomics' research into beneficial genes can support the development of non-GMO crops with enhanced traits, aligning with consumer preferences and opening new market avenues.
What Are FNAM's Competitive Advantages?
- Proprietary technology in the form of the Adapted Traits Platform.
- Established relationships with governmental and non-profit organizations.
- Expertise in identifying beneficial genes, providing a competitive edge.
What Does FNAM Do?
Evolutionary Genomics, Inc. was founded in 1990 and is headquartered in Castle Rock, Colorado. The company focuses on the investigation and identification of beneficial genes found in humans, various animal species, and commercial agricultural crops. Its proprietary Adapted Traits Platform is an advanced technological system designed to pinpoint specific genetic markers that can enhance desirable characteristics in plants. The platform aims to improve various traits, including increased crop yield, elevated sugar content, greater biomass production, enhanced drought tolerance, and superior resistance to pests and diseases. Evolutionary Genomics, Inc. serves a wide array of clients, including governmental organizations, non-profit foundations, and commercial enterprises, thereby establishing a diverse market presence. The company’s commitment to advancing agricultural biotechnology positions it as a key player in the sector, particularly as global demand for food security and sustainable agricultural practices continues to rise. With a small team of two employees, Evolutionary Genomics remains agile and focused on its mission to leverage genetic insights for agricultural advancements.
What Products and Services Does FNAM Offer?
- Investigate and identify beneficial genes in humans, animals, and commercial crops.
- Develop the Adapted Traits Platform for pinpointing genetic markers.
- Enhance agricultural traits such as yield, drought tolerance, and pest resistance.
- Serve a diverse clientele including governmental organizations and commercial enterprises.
- Focus on sustainable agricultural practices through genetic research.
How Does FNAM Make Money?
- Generate revenue through partnerships with governmental and non-profit organizations.
- Offer consulting services related to genetic research and agricultural enhancements.
- Develop proprietary technology for identifying beneficial genetic traits.
What Industry Does FNAM Operate In?
The biotechnology industry, particularly in the agricultural sector, is experiencing significant growth, driven by advancements in genetic research and increasing demand for sustainable farming practices. The global agricultural biotechnology market is expected to grow at a CAGR of 10% from 2022 to 2027, reaching approximately $50 billion. Evolutionary Genomics, Inc. is well-positioned within this landscape, focusing on enhancing crop traits that address critical issues such as climate change and food security. The competitive landscape includes larger firms with more resources, but Evolutionary Genomics' specialized focus on beneficial gene identification offers a niche advantage.
Who Are FNAM's Key Customers?
- Governmental organizations focused on agricultural research.
- Non-profit foundations supporting sustainable agriculture.
- Commercial enterprises in the agricultural sector seeking genetic enhancements.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 48 |
| 2026-08-26 | 48 |
| 2026-08-29 | 48 |
| 2026-09-01 | 48 |
| 2026-09-04 | 48 |
| 2026-09-07 | 48 |
| 2026-09-10 | 48 |
What changed?
The score has stayed at 48.
Over the same 18 days the stock moved +0.0%.
Company Profile
Evolutionary Genomics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Castle Rock, US. The company is led by CEO Steven Bryan Warnecke. FNAM has traded publicly since 2011.
Insider Activity
The most recent 12 insider filings for Evolutionary Genomics, Inc. break down as 8 sales and 4 purchases. On net that is roughly 67K shares disposed (about $7K), a signal worth weighing alongside the fundamentals.
Financial Health
Evolutionary Genomics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -14.34 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Evolutionary Genomics, Inc. stands at 64.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -82.2%, showing how much profit it generates from its asset base. A current ratio of 3.92 indicates the company holds enough short-term assets to cover its near-term obligations.
FNAM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary Adapted Traits Platform for identifying beneficial genes.
- Established presence in the biotechnology sector since 1990.
- Diverse clientele including government and commercial entities.
- Upcoming: Expansion of the Adapted Traits Platform to include new genetic markers.
Bear Case
- Limited workforce of only 2 employees, which may restrict operational capacity.
- No current revenue generation reported, indicating early-stage development.
- Dependence on external partnerships for funding and growth.
- Potential: Regulatory hurdles that could delay product development and market entry.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · June 2026
FNAM Latest News
No recent news available for FNAM.
FNAM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for FNAM.
Price Targets
Wall Street price target analysis for FNAM.
FNAM MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for FNAM; grades run from A+ (80-100) to F (below 30).
Leadership: Steve Warnecke
CEO
Steve Warnecke has been leading Evolutionary Genomics, Inc. since its inception in 1990. With a background in genetic research and biotechnology, he has been instrumental in developing the company's proprietary Adapted Traits Platform. Warnecke holds a degree in biology and has extensive experience in agricultural biotechnology.
Track Record: Under Steve Warnecke's leadership, Evolutionary Genomics has established itself as a key player in the biotechnology sector, focusing on sustainable agricultural practices. His strategic vision has led to the development of innovative solutions that address critical agricultural challenges.
FNAM OTC Market Information
The OTC Other tier includes companies that do not meet the listing requirements of major exchanges like NYSE or NASDAQ. This tier allows for trading of smaller companies that may have limited financial disclosures and lower liquidity.
- OTC Tier: OTC Other
- Limited financial disclosures may lead to uncertainty regarding the company's performance.
- Lower liquidity on the OTC market can result in higher volatility.
- Potential regulatory scrutiny affecting smaller biotech firms.
- Verify the company's financial health and operational metrics.
- Assess the credibility of management and their track record.
- Review any existing partnerships and contracts.
- Investigate the competitive landscape and market positioning.
- Examine the regulatory environment affecting the biotechnology sector.
- Established presence in the biotechnology industry since 1990.
- Development of proprietary technology in agricultural genetics.
- Diverse client base including governmental and non-profit organizations.
FNAM Healthcare Stock FAQ
Is FNAM a good stock?
Stock Expert AI does not rate FNAM buy, sell or hold. Evolutionary Genomics, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the main risks for FNAM?
Evolutionary Genomics, Inc. faces several risks, including regulatory hurdles that could impede product development and market entry. Additionally, the company competes with larger biotechnology firms that have more resources, which could impact its market position.
What are the key factors to evaluate for FNAM?
Evaluate FNAM on fundamentals, analyst consensus, and risk factors. Investors may want to evaluate these factors as they assess the company's potential for long-term success. Not financial advice.
How frequently does FNAM data refresh on this page?
FNAM's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven FNAM's recent stock price performance?
Evolutionary Genomics, Inc. (FNAM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Adapted Traits Platform for identifying beneficial genes. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider FNAM overvalued or undervalued right now?
Evolutionary Genomics, Inc. (FNAM) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of FNAM?
Yes, most major brokerages offer fractional shares of Evolutionary Genomics, Inc. (FNAM) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track FNAM's earnings and financial reports?
Evolutionary Genomics, Inc. (FNAM) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for FNAM earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial disclosures may affect the overall assessment of the company's performance.